指南与共识妇科肿瘤

子宫内膜癌临床研究:妇科肿瘤协作组共识推荐

Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
指南 / 共识 · Lancet Oncol · 2024-01-01

2023年11月2日至3日在韩国仁川召开的妇科肿瘤协作组(GCIG)子宫内膜癌临床研究共识会议,由全部33个成员组参与制定18条共识声明,涉及高危疾病辅助治疗、转移和复发疾病治疗、罕见亚组和特殊情况试验设计、低资源环境试验方法学,并确定8个未满足需求领域。18条中16条获一致共识,其余2条一致率97%。

要点

  • GCIG全部33个成员组参与制定18条共识声明,覆盖4个主题组。
  • 16条声明获一致共识,其余2条一致率为97%。
  • 会议确定8个未满足需求领域,并首次纳入患者倡导者及公平准入专家。

核心结论

  • 所有代表积极参与准备、讨论和 refine 声明后的高接受率证实了全球学术环境下的共识进展,并预期ECCC将促进全球子宫内膜癌患者临床研究更大的协调、落实、包容和未满足需求的解决。

研究设计与样本

  • GCIG子宫内膜癌临床研究共识会议于2023年11月2日至3日在韩国仁川举行,全部33个GCIG成员组参与制定、完善和最终确定18条声明,分属4个主题组。
  • 会议采用既往卵巢癌共识会议描述的方法学,首次纳入患者倡导者及包容、多样性、公平和准入专家参与全过程,并选入4名早期职业研究者代表不同成员组和区域。

主要发现

  • 18条声明中16条获得一致共识,其余2条一致率为97%。
  • 会议确定8个未满足需求领域。
  • 会议未要求任何少数意见声明。

关键数值与推荐

  • 18条声明覆盖4个主题组:高危疾病辅助治疗;转移和复发疾病治疗;罕见子宫内膜癌亚组和特殊情况的试验设计;低资源环境试验的特定方法学和调整。
  • 16条声明获一致共识,其余2条一致率97%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Consensus Conference on Clinical Research (ECCC) was held in Incheon, South Korea, Nov 2-3, 2023. The aims were to develop consensus statements for future trials in endometrial cancer to achieve harmonisation on design elements, select important questions, and identify unmet needs. All 33 GCIG member groups participated in the development, refinement, and finalisation of 18 statements within four topic groups, addressing adjuvant treatment in high-risk disease; treatment for metastatic and recurrent disease; trial designs for rare endometrial cancer subgroups and special circumstances; and specific methodology and adaptation for trials in low-resource settings. In addition, eight areas of unmet need were identified. This was the first GCIG Consensus Conference to include patient advocates and an expert on inclusion, diversity, equity, and access to take part in all aspects of the process and output. Four early-career investigators were also selected for participation, ensuring that they represented different GCIG member groups and regions. Unanimous consensus was obtained for 16 of the 18 statements, with 97% concordance for the remaining two. Using the described methodology from previous Ovarian Cancer Consensus Conferences, this conference did not require even one minority statement. The high acceptance rate following active involvement in the preparation, discussion, and refinement of the statements by all representatives confirmed the consensus progress within a global academic setting, and the expectation that the ECCC will lead to greater harmonisation, actualisation, inclusion, and resolution of unmet needs in clinical research for individuals living with and beyond endometrial cancer worldwide.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Creutzberg CL, Kim JW, Eminowicz G, et al. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2024. PMID: 39214113. doi:10.1016/S1470-2045(24)00192-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。